Strides arm gets US FDA nod for sterile injectables facility in Poland

The company will commence shipments from the Polish facility by the fourth quarter of 2012

Agila Specialties (Agila), an injectables business unit of Bangalore-based pharma company Arcolab Limited has received US FDA approval for its Polish Sterile facility located in Warswa, Poland. The unit manufactures vials, ampoules, pre-filled syringes and lyophilised injections. With this approval, all eight global sterile injectable sites of Agila are now approved by the and EU authorities and places Agila amongst the largest global capacities for sterile injectables.

The company will commence shipments from the Polish facility by the fourth quarter of 2012 and will run in full capacity by the first quarter of 2013 as product transfers have already commenced.

"This approval for our Polish sterile facility offers significant flexibility to our manufacturing which is currently experiencing strong demand on a worldwide basis," Venkat Iyer, CEO, Agila Specialties said.

Agila focusses on key domains such as oncolytics, penems, penicillins, cephalosporins, opthalmics, peptides and biosimilars. It operats from nine global manufacturing facilities, including India.

image
Business Standard
177 22
Business Standard

Strides arm gets US FDA nod for sterile injectables facility in Poland

The company will commence shipments from the Polish facility by the fourth quarter of 2012

BS Reporter  |  Bangalore 



Agila Specialties (Agila), an injectables business unit of Bangalore-based pharma company Arcolab Limited has received US FDA approval for its Polish Sterile facility located in Warswa, Poland. The unit manufactures vials, ampoules, pre-filled syringes and lyophilised injections. With this approval, all eight global sterile injectable sites of Agila are now approved by the and EU authorities and places Agila amongst the largest global capacities for sterile injectables.

The company will commence shipments from the Polish facility by the fourth quarter of 2012 and will run in full capacity by the first quarter of 2013 as product transfers have already commenced.

"This approval for our Polish sterile facility offers significant flexibility to our manufacturing which is currently experiencing strong demand on a worldwide basis," Venkat Iyer, CEO, Agila Specialties said.

Agila focusses on key domains such as oncolytics, penems, penicillins, cephalosporins, opthalmics, peptides and biosimilars. It operats from nine global manufacturing facilities, including India.

RECOMMENDED FOR YOU

Strides arm gets US FDA nod for sterile injectables facility in Poland

The company will commence shipments from the Polish facility by the fourth quarter of 2012

Agila Specialties (Agila), an injectables business unit of Bangalore-based pharma company Strides Arcolab Limited has received US FDA approval for its Polish Sterile facility located in Warswa, Poland. The unit manufactures vials, ampoules, pre-filled syringes and lyophilised injections. With this approval, all eight global sterile injectable sites of Agila are now approved by the USFDA and EU authorities and places Agila amongst the largest global capacities for sterile injectables.

Agila Specialties (Agila), an injectables business unit of Bangalore-based pharma company Arcolab Limited has received US FDA approval for its Polish Sterile facility located in Warswa, Poland. The unit manufactures vials, ampoules, pre-filled syringes and lyophilised injections. With this approval, all eight global sterile injectable sites of Agila are now approved by the and EU authorities and places Agila amongst the largest global capacities for sterile injectables.

The company will commence shipments from the Polish facility by the fourth quarter of 2012 and will run in full capacity by the first quarter of 2013 as product transfers have already commenced.

"This approval for our Polish sterile facility offers significant flexibility to our manufacturing which is currently experiencing strong demand on a worldwide basis," Venkat Iyer, CEO, Agila Specialties said.

Agila focusses on key domains such as oncolytics, penems, penicillins, cephalosporins, opthalmics, peptides and biosimilars. It operats from nine global manufacturing facilities, including India.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard